intranasal drug delivery

Beyond Barriers Therapeutics (BBT) is a clinical-stage biotechnology company developing BBT-101, a first-of-its-kind intranasal therapeutic designed to mitigate the damaging secondary effects of mild traumatic brain injuries (mTBI, also known as concussions) and moderate TBIs. The company began as the brainchild of University of Chicago and Northwestern graduate students who in 2015 won the NIH Neuro Startup Challenge. BBT is affiliated with the University of Miami through a research collaboration with Dr. Michael Hoffer.

Read more

clinical-stage therapeutic development